JP2023514742A - がん及び腫瘍を処置する組成物及び方法 - Google Patents

がん及び腫瘍を処置する組成物及び方法 Download PDF

Info

Publication number
JP2023514742A
JP2023514742A JP2022550805A JP2022550805A JP2023514742A JP 2023514742 A JP2023514742 A JP 2023514742A JP 2022550805 A JP2022550805 A JP 2022550805A JP 2022550805 A JP2022550805 A JP 2022550805A JP 2023514742 A JP2023514742 A JP 2023514742A
Authority
JP
Japan
Prior art keywords
day
body weight
cancer
tumor
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022550805A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023514742A5 (enExample
Inventor
ウク カン，シン
キム，キョンスン
ヘ スン，チ
Original Assignee
オブラート，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オブラート，インコーポレーテッド filed Critical オブラート，インコーポレーテッド
Publication of JP2023514742A publication Critical patent/JP2023514742A/ja
Publication of JP2023514742A5 publication Critical patent/JP2023514742A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022550805A 2020-02-24 2021-02-24 がん及び腫瘍を処置する組成物及び方法 Pending JP2023514742A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062980645P 2020-02-24 2020-02-24
US62/980,645 2020-02-24
PCT/US2021/019457 WO2021173702A1 (en) 2020-02-24 2021-02-24 Compositions and methods for treating cancer and tumor

Publications (2)

Publication Number Publication Date
JP2023514742A true JP2023514742A (ja) 2023-04-07
JP2023514742A5 JP2023514742A5 (enExample) 2024-03-04

Family

ID=77490220

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022550805A Pending JP2023514742A (ja) 2020-02-24 2021-02-24 がん及び腫瘍を処置する組成物及び方法

Country Status (8)

Country Link
US (1) US20230092005A1 (enExample)
EP (1) EP4110315A4 (enExample)
JP (1) JP2023514742A (enExample)
KR (1) KR20220145861A (enExample)
CN (1) CN115151250A (enExample)
AU (1) AU2021228654A1 (enExample)
CA (1) CA3168980A1 (enExample)
WO (1) WO2021173702A1 (enExample)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120197059A1 (en) * 2011-01-31 2012-08-02 Yunzhou Dong Ubiquitin interacting motif peptides as cancer therapeutics
US20150258046A1 (en) * 2008-02-12 2015-09-17 Tosk, Inc. Doxorubicin Adjuvants to Reduce Toxicity and Methods for Using the Same
US20170027891A1 (en) * 2008-09-02 2017-02-02 Oklahoma Medical Research Foundation Adjuvant chemotherapy for anaplastic gliomas
US20180200192A1 (en) * 2017-01-19 2018-07-19 Otologic Pharmaceutics, Inc. Formulations of n-acetylcysteine and uses thereof
WO2018174506A1 (ko) * 2017-03-20 2018-09-27 아주대학교산학협력단 Sulf2 유전자를 이용한 소라페닙 치료에 대한 감수성 예측방법 및 sulf2 저해제를 포함하는 암 치료용 조성물
WO2019060152A1 (en) * 2017-09-20 2019-03-28 Oklahoma Medical Research Foundation TREATMENT OF DRUG-RESISTANT GLIOMES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
EP3787750A1 (en) * 2018-05-03 2021-03-10 Hough Ear Institute Methods for reducing accumulated pathologic tau protein

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150258046A1 (en) * 2008-02-12 2015-09-17 Tosk, Inc. Doxorubicin Adjuvants to Reduce Toxicity and Methods for Using the Same
US20170027891A1 (en) * 2008-09-02 2017-02-02 Oklahoma Medical Research Foundation Adjuvant chemotherapy for anaplastic gliomas
US20120197059A1 (en) * 2011-01-31 2012-08-02 Yunzhou Dong Ubiquitin interacting motif peptides as cancer therapeutics
US20180200192A1 (en) * 2017-01-19 2018-07-19 Otologic Pharmaceutics, Inc. Formulations of n-acetylcysteine and uses thereof
WO2018174506A1 (ko) * 2017-03-20 2018-09-27 아주대학교산학협력단 Sulf2 유전자를 이용한 소라페닙 치료에 대한 감수성 예측방법 및 sulf2 저해제를 포함하는 암 치료용 조성물
WO2019060152A1 (en) * 2017-09-20 2019-03-28 Oklahoma Medical Research Foundation TREATMENT OF DRUG-RESISTANT GLIOMES

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GENES, CHROMOSOMES & CANCER, vol. 52, no. 3, JPN6025031953, 2012, pages 225 - 236, ISSN: 0005807104 *
ONCOGENE, vol. 29, no. 5, JPN6025031952, 2009, pages 635 - 646, ISSN: 0005807103 *
PLOS ONE, vol. Vol.10, No. 8, e0134276, JPN6025031957, 2015, pages 1 - 29, ISSN: 0005807106 *
TRANSLATIONAL ONCOLOGY, vol. 12, no. 2, JPN6025031955, 2018, pages 320 - 335, ISSN: 0005807105 *
岩手医学雑誌, vol. 71巻3号, JPN6024053109, 2019, pages 99 - 108, ISSN: 0005656651 *
日本内科学会雑誌, vol. 99巻9号, JPN6024053111, 2010, pages 2035 - 2051, ISSN: 0005656653 *
電気泳動, vol. 62巻1号, JPN6024053110, 2018, pages 9 - 12, ISSN: 0005656652 *

Also Published As

Publication number Publication date
CN115151250A (zh) 2022-10-04
US20230092005A1 (en) 2023-03-23
KR20220145861A (ko) 2022-10-31
WO2021173702A1 (en) 2021-09-02
EP4110315A1 (en) 2023-01-04
AU2021228654A1 (en) 2022-10-13
CA3168980A1 (en) 2021-09-02
EP4110315A4 (en) 2024-03-06
WO2021173702A8 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
RU2483714C2 (ru) Наночастица, содержащая рапамицин и альбумин, в качестве противоракового агента
US12059397B2 (en) Calcium lactate compositions and methods of use
AU2020222296A1 (en) Pharmaceutical combination comprising tno155 and ribociclib
CZ20013614A3 (cs) Terapeutický farmaceutický přípravek
JP2018501218A (ja) 併用療法
JP2020505433A (ja) Ｈｓｐ９０阻害剤を使用してがんを治療するための方法
US12213958B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
KR20240163084A (ko) 유방암에 대한 복합 요법
US20240285640A1 (en) Combination therapy for treating pik3ca-mutated cancer
TWI771344B (zh) 一種ｖｅｇｆｒ抑制劑與ｐａｒｐ抑制劑聯合在製備治療胃癌的藥物中的用途
KR20240158972A (ko) 소세포 폐암의 치료 방법
JP2023514742A (ja) がん及び腫瘍を処置する組成物及び方法
TW202337897A (zh) 抗ｐｄ－１抗體和抗ｖｅｇｆ－ａ抗體的藥物組合及其使用方法
TW202308641A (zh) 用於治療癌症之方法及包含cdk抑制劑之給藥方案
US11484591B2 (en) Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
US20230058726A1 (en) Chemoprevention using controlled- release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
AU2015271950B2 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
TWI843217B (zh) 一種藥物組合及其應用
WO2019070497A1 (en) POLY THERAPY AGAINST CANCER
US20210113692A1 (en) Dosing regimen
RU2777519C2 (ru) Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы
US20210236418A1 (en) Composition and Method for Oral Treatment of Leukemia
JP2026500734A (ja) 医薬組み合わせ、及びその使用
Chen et al. Preclinical activity of the rational combination of apatinib in combination with CPT-11 in KRAS-mutant colorectal cancer patient-derived xenograft model
HK40105345A (zh) 治疗癌症的组合物和方法

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20221214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251030

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260303